- Americans more likely than others to prefer generics, study finds
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
- Roxane Labs' generic prostate drug gets tentative approval from FDA
HYDERABAD, India — Indian generic drug maker Dr. Reddy’s Labs has launched a generic treatment for seasonal allergies, the company said Tuesday.
Dr. Reddy’s announced the launch of levocetirizine tablets in the 5-mg strength. The drug is a generic version of UCB’s and Sanofi-Aventis’ Xyzal.
Levocetirizine had sales of about $238 million during the 12-month period ended in September 2010, according to IMS Health.